Updated Results of BCMA/CD19 Dual-targeting Fast CAR-T GC012F Dual-targeting CAR-T in RRMM | International Myeloma Foundation
IJMS | Free Full-Text | Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
TNFRSF17/BCMA (E6D7B) Rabbit mAb (PE Conjugate) | Cell Signaling Technology
Frontiers | Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Teclistamab Monotherapy for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma - touchONCOLOGY
CD3/BCMA Bispecific Antibody for Multiple Myeloma Treatment - Protheragen
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy | SpringerLink
IJMS | Free Full-Text | Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms
BCMA-targeted immunotherapy for multiple myeloma | Journal of Hematology & Oncology | Full Text
ACROBiosystems Human BCMA / TNFRSF17 Protein,His Tag DMF Filed 100 ug ACROBiosystems Human BCMA / TNFRSF17 Protein,His Tag DMF Filed | Fisher Scientific
T-Cell Therapies mid-2020 Update - Blue Matter Consulting
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma: Molecular Therapy
Frontiers | Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting
L'antigène de maturation des cellules B (BCMA),une cible pour le myélome multiple - ACROBiosystems
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment - ScienceDirect
A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells - ScienceDirect
CAR T-cell therapy in multiple myeloma: more room for improvement | Blood Cancer Journal
B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages | Journal of Translational Medicine | Full Text
Recombinant Human BCMA protein (ABIN4949075)
Hemato | Free Full-Text | Why Immunotherapy Fails in Multiple Myeloma
CD3/BCMA Bispecific Antibody for Multiple Myeloma Treatment - Protheragen
